SRR8942993
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.570
- WNT_BETA_CATENIN_SIGNALING+0.480
- IL6_JAK_STAT3_SIGNALING+0.290
- ANGIOGENESIS+0.270
- ALLOGRAFT_REJECTION+0.260
- TNFA_SIGNALING_VIA_NFKB+0.250
- APICAL_JUNCTION+0.160
- INTERFERON_ALPHA_RESPONSE+0.160
- P53_PATHWAY+0.130
- HEME_METABOLISM+0.110
Top 10 suppressed
- E2F_TARGETS-0.520
- CHOLESTEROL_HOMEOSTASIS-0.460
- G2M_CHECKPOINT-0.420
- MTORC1_SIGNALING-0.370
- FATTY_ACID_METABOLISM-0.340
- SPERMATOGENESIS-0.340
- XENOBIOTIC_METABOLISM-0.330
- PANCREAS_BETA_CELLS-0.300
- ESTROGEN_RESPONSE_LATE-0.250
- ADIPOGENESIS-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-03233 | — | cohortA1 | 0.759 |
| 2 | TCGA-AC-A2QI-01A-12R-A19W-07 | — | A | 0.756 |
| 3 | SRR8943004 | — | — | 0.754 |
| 4 | SRR8942946 | — | — | 0.752 |
| 5 | MNG991 | — | — | 0.743 |
| 6 | 102d912c-5882-4ae4-9eaf-cbd2f55f66af | — | — | 0.741 |
| 7 | SRR12202458 | — | — | 0.736 |
| 8 | 20110029.TNBC | — | D | 0.735 |
| 9 | TCGA-78-8655-01A-11R-2403-07 | — | cohortA1 | 0.731 |
| 10 | TCGA-PK-A5HA-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.730 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.570 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.480 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.260 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.160 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.130 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.110 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.110 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.110 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| COMPLEMENT | 0.090 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.090 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.080 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.040 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.030 | Inavolisib | — uncovered |